secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-014267
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026
--------------------------------------------------------------------------------

- 66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.
- Blinded aggregate response rate in FLASH 2 remains higher than estimated rate used to design study, increasing confidence.
- Investigator-initiated study: 75% of patients achieved treatment success, 3 complete responses with HyBryte at 18 weeks.
- Cash ~$10.5M as of Sep 30, 2025, plus ~$500k from NJ NOL program; runway through 2026.
- Positive Phase 2a results for SGX945 (Behçet’s) and SGX302 (psoriasis); Phase 2b design underway in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000110465926014267/0001104659-26-014267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000110465926014267/sngx-20260212x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-014267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer